Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.32 -14.8%	$0.39	$0.30 ▼ $10.62	$53.80M	1.86	3.46 million shs	13.30 million shs
GNFT GENFIT	$3.61 -6.0%	$4.11	$2.55 ▼ $6.42	$191.99M	1.15	10,530 shs	22,737 shs
LRMR Larimar Therapeutics	$3.03 -1.6%	$2.41	$1.61 ▼ $11.20	$197.21M	0.79	851,133 shs	1.91 million shs
SLS SELLAS Life Sciences Group	$1.95 -3.9%	$1.63	$0.77 ▼ $2.12	$202.55M	2.25	1.68 million shs	15.87 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	-14.79%	-5.57%	-14.13%	-37.28%	-92.74%
GNFT GENFIT	-5.99%	-7.08%	-16.24%	-0.39%	-3.73%
LRMR Larimar Therapeutics	-1.62%	+16.99%	+52.26%	+28.94%	-56.84%
SLS SELLAS Life Sciences Group	-3.94%	+26.62%	+9.55%	+75.68%	+74.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	4.0352 of 5 stars	3.3	1.0	4.7	2.2	1.7	1.3
GNFT GENFIT	2.2416 of 5 stars	3.5	4.0	0.0	2.7	0.0	0.0
LRMR Larimar Therapeutics	1.9854 of 5 stars	3.6	1.0	0.0	3.0	1.7	0.0
SLS SELLAS Life Sciences Group	0.3651 of 5 stars	0.0	1.0	0.0	2.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,783.88% Upside
GNFT GENFIT	3.00	Buy	$13.00	260.11% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	510.56% Upside
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest APLT, SLS, GNFT, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
5/14/2025	APLT Applied Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$1.50 ➝ $1.50

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$460K	99.66	N/A	N/A	$0.49 per share	0.66
GNFT GENFIT	$76.77M	2.35	$0.07 per share	54.90	$1.50 per share	2.41
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
SLS SELLAS Life Sciences Group	$1M	194.57	N/A	N/A	$0.13 per share	15.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.43	N/A	N/A	N/A	N/A	-184.67%	-84.02%	8/6/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)

Latest APLT, SLS, GNFT, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
4/30/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A
4/14/2025	Q4 2024	APLT Applied Therapeutics	-$0.18	-$0.24	-$0.06	$0.33	$0.61 million	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	3.00	3.00
GNFT GENFIT	0.08	1.23	1.23
LRMR Larimar Therapeutics	N/A	7.48	7.48
SLS SELLAS Life Sciences Group	N/A	4.64	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
GNFT GENFIT	2.24%
LRMR Larimar Therapeutics	91.92%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
GNFT GENFIT	4.20%
LRMR Larimar Therapeutics	4.50%
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	141.58 million	139.31 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	98.38 million	Not Optionable

APLT, SLS, GNFT, and LRMR Headlines

Recent News About These Companies

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Increase in Short Interest

June 16, 2025 | marketbeat.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

Nostrand Robert L. Van Acquires 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 13, 2025 | marketbeat.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

Insider Buying: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Purchases 20,000 Shares of Stock

June 3, 2025 | marketbeat.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 Shares

June 3, 2025 | insidertrades.com

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

594,919 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Bought by Brooklyn FI LLC

May 28, 2025 | marketbeat.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.comF

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | finanznachrichten.de

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | globenewswire.com

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025

April 28, 2025 | quiverquant.comQ

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

April 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT, SLS, GNFT, and LRMR Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.32 -0.06 (-14.79%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.35 +0.02 (+6.86%)

As of 06/27/2025 07:10 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

GENFIT NASDAQ:GNFT

$3.81 -0.03 (-0.78%)

As of 06/27/2025 04:00 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Larimar Therapeutics NASDAQ:LRMR

$3.03 -0.05 (-1.62%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.00 -0.03 (-1.16%)

As of 06/27/2025 07:55 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

SELLAS Life Sciences Group NASDAQ:SLS

$1.95 -0.08 (-3.94%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.96 +0.01 (+0.51%)

As of 06/27/2025 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time